US20150157595A1 - Methods of treating a subject with benign prostate hyperplasia - Google Patents
Methods of treating a subject with benign prostate hyperplasia Download PDFInfo
- Publication number
- US20150157595A1 US20150157595A1 US14/327,097 US201414327097A US2015157595A1 US 20150157595 A1 US20150157595 A1 US 20150157595A1 US 201414327097 A US201414327097 A US 201414327097A US 2015157595 A1 US2015157595 A1 US 2015157595A1
- Authority
- US
- United States
- Prior art keywords
- prostate
- inhibitor
- metap
- administration
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZEZFKUBILQRZCK-FFPLEORUSA-N [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CCC12CO2 Chemical compound [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CCC12CO2 ZEZFKUBILQRZCK-FFPLEORUSA-N 0.000 description 2
- ZEZFKUBILQRZCK-MJSCXXSSSA-N [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CC[C@]12CO2 Chemical compound [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CC[C@]12CO2 ZEZFKUBILQRZCK-MJSCXXSSSA-N 0.000 description 2
- FEZNXMMLVZQOPC-WUDGAQTFSA-N CCN(CC)C/C=C\C1=C(S(=O)(=O)CC2=CC=C3CCCCC3=C2C(=O)O)C=CC=C1.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CCC12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCCN(C)C)C(C)C)CC[C@]12CO2 Chemical compound CCN(CC)C/C=C\C1=C(S(=O)(=O)CC2=CC=C3CCCCC3=C2C(=O)O)C=CC=C1.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)/C=C/C2=CC=C(OCCN(C)C)C=C2)CCC12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCCN(C)C)C(C)C)CC[C@]12CO2 FEZNXMMLVZQOPC-WUDGAQTFSA-N 0.000 description 1
- YHYZIQWRVAHZEC-JXVSDTTKSA-N [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)CC2CN3CCC2CC3)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)CCCC2CCCN2C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCC2CCCN2C)C(C)C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCN2CCCC2)C(C)C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(N)=O)C(C)C)CC[C@]12CO2 Chemical compound [H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)CC2CN3CCC2CC3)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)CCCC2CCCN2C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCC2CCCN2C)C(C)C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(=O)NCCN2CCCC2)C(C)C)CC[C@]12CO2.[H][C@]1([C@@]2(C)O[C@@H]2CC=C(C)C)[C@H](OC)[C@H](OC(=O)C[C@@H](C(N)=O)C(C)C)CC[C@]12CO2 YHYZIQWRVAHZEC-JXVSDTTKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00547—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
- A61B2018/1861—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves with an instrument inserted into a body lumen or cavity, e.g. a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B2018/2005—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser with beam delivery through an interstitially insertable device, e.g. needle
Definitions
- Benign Prostate Hyperplasia also called prostate enlargement, occurs in almost all men as they age. About half of men in their 60s have at least some symptoms of BPH.
- the prostate is the semen-producing gland that surrounds the urethra, the tube that carries urine from the bladder out of the body. Symptoms of BPH result when the prostate gland grows to the extent that it blocks the flow of urine through the urethra. This blockage may cause urinary problems, including an inability to completely empty the bladder, a frequent urge to urinate, a weak urine stream, nocturia, and hematuria. In some cases, these urinary problems lead to more serious complications, including urinary tract infections; bladder damage, stones, or infection; and kidney damage.
- Medications used to control prostate growth include alpha blockers and 5-alpha reductase inhibitors.
- Alpha blockers may act by relaxing the muscles around the bladder neck, which makes urination easier.
- Alpha blockers approved by the Food and Drug Administration to treat BPH are terazosin (Hytrin®), doxazosin (Cardura®), tamsulosin (Flomax®) and alfuzosin (Uroxatral®).
- the long-term effects of alpha-blockers are unknown and side effects include interactions with drugs taken to treat impotence and dizziness and lightheadedness upon standing.
- 5-alpha reductase inhibitors such as finasteride (Proscar®) and dutasteride (Avodart®) set by shrinking the prostate.
- 5-alpha reductase drugs may only be effective in subjects with large prostates and not in subjects with moderately-enlarged or normal-sized prostates.
- 5-alpha reductase drugs may take up to a year to produce therapeutic effects, may decrease libido, and may interfere with accurate reading of PSA tests, which are used to diagnose prostate cancer.
- Non-invasive procedures used to treat BPH include transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents.
- TUMT, TUNA, and ILT involve the use of heat produced by microwaves, radio waves, and lasers, respectively, to destroy prostate tissue blocking the urethra.
- TUMT, TUNA, and ILT may be less effective for large prostates, and the long-term effectiveness of these procedures is unknown.
- Prostatic stents are metal coils used to prop open the urethra. Stents are typically used in subjects unwilling or unable to take medications and/or have surgery, and are typically not considered to be a long-term treatment option.
- Surgeries to treat BPH include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, and open prostatectomy.
- TURP transurethral resection of the prostate
- TUIP transurethral incision of the prostate
- laser surgery and open prostatectomy.
- a narrow instrument is inserted into the urethra and used to scrape away prostate tissue surrounding the urethra.
- TUIP is performed similarly to TURP, but only one or two cuts is the prostate are made to relieve the pressure on the urethra.
- Laser surgery such as photosensitive vaporization of the prostate (PVP) and holium laser enucleation of the prostate (HoLEP) involve the use of lasers to destroy prostate tissue.
- PVP photosensitive vaporization of the prostate
- HoLEP holium laser enucleation of the prostate
- the prostate In an open prostatectomy, the prostate is accessed through an incision is made in a subject's lower abdomen (rather than through the urethra), and the inner portion of the prostate is removed.
- a subject who undergoes surgery to treat BPH may require additional surgeries if the prostate grows back. Side effects, such as impotence, incontinence, infection and scarring, may occur.
- Medications, non-invasive procedures and surgeries known in the art for treating BPH may not be as effective as desired and often produce side effects. Methods of treating subjects with BPH that are more effective than current therapies, e.g., surgery, are clearly needed.
- this disclosure provides for a method for treating benign prostatic hypertrophy (BPH) and related disorders, in a male subject in need thereof, comprising administering (e.g. parenterally, intravenously, subcutaneously, orally), a therapeutically effective amount of a MetAP-2.
- BPH benign prostatic hypertrophy
- Such methods may result in reduction in the rate of growth of the subject's prostate, for example, such methods may provide for a decrease in the prostate of said male subject by at least 25% within 30 days.
- Contemplated MetAP-2 inhibitors include fumagillin-based compounds.
- Provided methods may, in some embodiments, further comprise administering an additional therapeutic agent, for example, an alpha blocker (e.g. terazosin, doxazosin, tamsulosin and alfuxosin), a 5 alpha reductase inhibitor (e.g. finasteride and dutasteride), saw palmetto, beta-sitosterol, and pygeum.
- an alpha blocker e.g. terazosin, doxazosin, tamsulosin and alfuxosin
- a 5 alpha reductase inhibitor e.g. finasteride and dutasteride
- saw palmetto beta-sitosterol
- beta-sitosterol pygeum
- contemplated methods may further comprise administering a non-invasive procedure, such as transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), or prostatic stents, and/or may further comprise administering a surgical treatment, such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, or open prostatectomy.
- a non-invasive procedure such as transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), or prostatic stents
- a surgical treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, or open prostatectomy.
- MetAP-2 inhibitors may be, for example, represented by Compound 1:
- MetAP-2 inhibitors may be administered as a dose of about 0.01 mg/kg to about 10 mg/kg, or about 0.04 mg/kg to about 1.0 mg/kg.
- Also provided herein is a method for reducing the prostate gland in a male subject in need thereof, comprising administering a therapeutically effective amount of a MetAP-2 inhibitor to the male subject.
- the disclosure relays at least in part to methods for treating a prostate condition, such as BPH, which include administering a MetAP2 inhibitor.
- MetAP2 encodes a protein that functions at least in part by enzymatically removing the amino terminal methionine residue from certain newly translated proteins. Increased expression of the MetAP2 gene has been historically associated with various forms of cancer. Molecules inhibiting the enzymatic activity of MetAP2 have been identified and have been explored for their utility in the treatment of various tumor types (Wang et al. (2003) Cancer Res. 63:7861) and infectious diseases such as microsporidiosis, leishmaniasis, and malaria (Zhang et a). (2002) J. Biomed. Sci. 9:34). While BPH is not a form of cancer, it has been found that MetAP2 inhibitors can effectively treat subjects with BPH. Disclosed herein are methods relating to administering a MetAP-2 inhibitor to treat a prostate condition, e.g., BPH.
- BPH may be diagnosed based on an evaluation of a subject's reported symptoms and family history, as well as by the results of one or more tests including a digital rectal exam, urine test, blood test, transrectal ultrasound (TRUS), urodynamic pressure-flow studies, cystoscopy, intravenous pyelogram or CT urogram, prostate-specific antigen (PSA) blood test, urinary flow test and postvoid residual volume test.
- TRUS transrectal ultrasound
- PSA prostate-specific antigen
- MetAP2 inhibitors refer to a class of molecules that inhibit the activity of MetAP2, e.g., the ability of MetAP2 to cleave the N-terminal methionine residue of newly synthesized proteins to produce the active form of the protein, or the ability of MetAP2 to regulate protein synthesis by protecting the sub-unit of eukaryotic initiation factor-2 (eIf2) from phosphorylation.
- eIf2 eukaryotic initiation factor-2
- Exemplary MetAP2 inhibitors may include irreversible inhibitors that covalently bind to MetAP2.
- irreversible inhibitors include fumagillin, fumagillol, and fumagillin ketone.
- Derivatives and analogs of fumagillin, and pharmaceutically acceptable salts thereof are contemplated herein as irreversible MetAP2 inhibitors, such as O-(4-dimethylaminoethoxycinnamoyl)fumagillol (CKD-732, also referred to herein as Compound A), O-(3,4,5-trimethoxycinnamoyl)fumagillol, O-(4-chlorocinnamoyl)fumagillol; O-(4-aminocinnamoyl)fumagillol; O-(4-dimethylaminoethoxycinnamoyl)fumagillol; O-(4-methoxycinnamoyl)fumagillol O-(4-dimethylaminocinnamoyl)fumagillol; O-(4-hydroxycinnamoyl)fumagillol; O-(3,4-dimethoxycinnamo
- Fumagillin, and some derivatives thereof have a carboxylic acid moiety and can be administered in the form of the free acid.
- pharmaceutically acceptable salts of fumagillin, fumagillol, and derivatives thereof illustratively include those that can be made using the following bases: ammonia, L-arginine, benethamine, benzathene, betaine, bismuth, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)pyrrolidine, sodium hydroxide, triethanolamine, zinc hydroxide, dicyclohexlamine, or any other electron pair donor (as described in Handbook of
- Esters of the present invention may be prepared by reacting fumagillin or fumagillol with the appropriate acid under standard esterification conditions described in the literature (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis).
- Suitable fumagillin esters include ethyl methanoate, ethyl ethanoate, ethyl propanoate, propyl methanoate, propyl ethanoate, and methyl butanoate.
- irreversible inhibitors of MetAP2 may include a siRNA, shRNA, an antibody or an antisense compound of MetAP2.
- MetAP2 inhibitors are provided in the following references, each of which is hereby incorporated by reference; Olson et al. (U.S. Pat. No. 7,084,108 and WO 2002/042295), Olson et al. (U.S. Pat. No. 6,548,477; U.S. Pat. No. 7,037,890; U.S. Pat. No. 7,084,108; U.S. Pat. No. 7,268,111; and WO 2002/042295), Olson et al. (WO 2005/066197), Hong et al. (U.S. Pat. No. 6,040,337), Hong et al. (U.S. Pat. No.
- contemplated MetAP2 inhibitors do not include fumagillin, fumagillol, fumagillin ketone, CKD-732/compound A, and/or TNP-470.
- contemplated MetAP2 inhibitors may include:
- a method of treating a condition affecting the prostate, e.g., benign prostate hyperplasia (BPH), in a subject in need thereof comprising parenterally or non-parenterally administering a therapeutically effective amount of a MetAP2 inhibitor to said subject.
- a contemplated therapeutically effective amount of a MetAP2 as described below does not substantially modulate or suppress angiogenesis, but is still effective as MetAP2 inhibitor.
- angiogenesis is known to persons skilled in the art, and refers to the process of new blood vessel formation, and is essential for the exponential growth of solid tumors and tumor metastasis.
- a method of treating a condition affecting the prostate in a subject in need thereof comprising administering a therapeutically effective amount of a MetAP2 inhibitor to said subject, wherein substantially no loss of new blood vessels in the prostate or other tissue compartments occur as compared to a subject being treated for a prostate condition with, e.g., surgery.
- disclosed methods upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in a reduction in the rate of prostate growth in a male-subject of at least a 5%, 10%, 20%, or 30%, or more based on the prostate's original rate of growth. In some embodiments, disclosed methods, upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in a reduction in the size of a prostate of at least a 5%, 10%, 20%, or 30%, or more based on the original size of the prostate.
- reduction in size of the prostate following treatment with therapeutically effective doses of MetAP2 inhibitors may substantially cease once a subject attains a desired prostate size, i.e., a size that reduces and/or eliminates symptoms, e.g. urinary symptoms, of a prostate condition, e.g. BPH.
- Some methods disclosed herein may involve co-administration of another BPH treatment, such as a therapeutic agent.
- Therapeutic agents include but are not limited to alpha blockers, e.g., terazosin (Hytrin®), doxazosin (Cardura®), tamsulosin (Flomax®) and alfuzosin (Uroxatral®), 5-alpha reductase inhibitors, e.g., finasteride (Proscar®) and dutasteride (Avodart®), saw palmetto, beta-sitosterol, and pygeum.
- alpha blockers e.g., terazosin (Hytrin®), doxazosin (Cardura®), tamsulosin (Flomax®) and alfuzosin (Uroxatral®
- 5-alpha reductase inhibitors e.g., finasteride (Proscar®) and dutasteride (Avodart®
- contemplated methods include co-administration of a non-invasive procedure, e.g., transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents.
- a non-invasive procedure e.g., transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents.
- a surgical treatment e.g. transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, and open prostatectomy.
- co-administration of a MetAP-2 inhibitor and another BPH treatment occur at the same time.
- administration of a MetAP-2 inhibitor occurs immediately prior to or immediately after another BPH treatment.
- a period of time may elapse between administration of a MetAP-2 inhibitor and another BPH treatment.
- a male subject may be administered prostate surgery to reduce the size of the prostate, followed by a recovery period of, e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, or 6 months or longer, after which time the male subject is administered a MetAP-2 inhibitor to reduce the rate of re-growth of the prostate.
- a subject may have a lower systemic exposure (e.g. at least about 2, 3, 5, 10, 20, or at least about 30% less systemic exposure) to the non-parenterally (e.g. orally) administered of a MetAP2 inhibitor as compared to a subject parenterally (e.g. subcutaneously) administered the same dose of the MetAP2 inhibitor.
- non-parenterally (e.g. orally) administered MetAP2 inhibitors may bind less to MetAP2 as compared to parenterally (e.g. subcutaneously) administered MetAP2 inhibitors.
- Contemplated non-parenteral administration includes oral, buccal, transdermal (e.g. by a dermal patch), topical, inhalation, sublingual, ocular, pulmonary, nasal, or rectal administration.
- Contemplated parenteral administration includes intravenous and subcutaneous administration, as well as administration at a site of a minimally-invasive procedure or a surgery.
- angiogenesis in another embodiment, provided herein are effective dosages, e.g. a daily dosage of a MetAP2 inhibitor, that may not substantially modulate or suppress angiogenesis.
- methods that include administering doses of MetAP2 inhibitors that are effective for reducing the rate of growth of the prostate, but are significantly smaller doses than that necessary to modulate and/or suppress angiogenesis (which may typically require about 12.5 mg/kg to about 50 mg/kg or more).
- contemplated dosage of a MetAP2 inhibitor in the methods described herein may include administering about 25 mg/day, about 10 mg/day, about 5 mg/day, about 3 mg/day, about 2 mg/day, about 1 mg/day, about 0.75 mg/day, about 0.5 mg/day, about 0.1 mg/day, about 0.05 mg/day, or about 0.01 mg/day.
- an effective amount of the drug for reducing the rate of prostate growth in a male subject may be about 0.0001 mg/kg to about 25 mg/kg of body weight per day.
- a contemplated dosage may from about 0.001 to 10 mg/kg of body weight per day, about 0.001 mg/kg to 1 mg/kg of body weight per day, about 0.001 mg/kg to 0.1 mg/kg of body weight per day or about 0.005 to about 0.04 mg/kg or about 0.005 to about 0.049 mg/kg of body weight a day.
- a MetAP2 inhibitor such as disclosed herein (e.g.
- O-(4-dimethylaminoethyoxycinnamoyl)fumagillol may be administered about 0.005 to about 5 mg/kg, or so about 5 mg/kg, or about 0.005 to about 0.1 mg/kg of a subject.
- a method for treating a prostate condition in a male subject in need thereof comprising administering, parenterally (e.g. intravenously) or non-parenterally, about 0.005 to about 0.04 mg/kg of a MetAP2 inhibitor selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable-salts thereof (for example, an oxalate salt), to said subject.
- a MetAP2 inhibitor selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable-salts thereof (for example, an oxalate salt)
- Such a method upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in at least a 10%, 20%, 30%, or 40% or more reduction in the rate of growth of the prostate.
- Contemplated methods may include administration of a composition comprising a MetAP2 inhibitor, for example, hourly, twice hourly, every three to four hours, daily, twice daily, 1, 2, 3 or 4 times a week, every three to four days, every week, or once every two weeks depending on half-life and clearance rate of the particular composition or inhibitor.
- a composition comprising a MetAP2 inhibitor, for example, hourly, twice hourly, every three to four hours, daily, twice daily, 1, 2, 3 or 4 times a week, every three to four days, every week, or once every two weeks depending on half-life and clearance rate of the particular composition or inhibitor.
- compositions may be administered on a regimen of, for example, one to four or more times per day.
- a suitable treatment period may be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely.
- a treatment period may terminate when a desired result, for example desired prostate size, is achieved. For example, treatment may terminate when reduction of about 20% of the prostate, about 30% of the prostate or more has been achieved.
- a treatment regimen may include a corrective phase, during which a MetAP2 inhibitor dose sufficient to provide reduction of prostate size is administered, followed by a maintenance phase, during which a lower MetAP2 inhibitor dose sufficient to reduce or prevent growth is administered.
- MetAP2 inhibitors may be formulated with conventional excipients to prepare an inhalable composition in the form of a fine powder or atomizable liquid.
- MetAP2 inhibitors may be formulated with conventional excipients, for example, in the form of eye drops or an ocular implant.
- excipients useful in eye drops are viscosifying or gelling agents, to minimize loss by lacrimation through improved retention in the eye.
- Liquid dosage forms for oral, or other administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl-alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents such as, for example, water or other solvents
- Dosage forms for topical or transdermal administration of an inventive pharmaceutical composition may include ointments, pastes, creams, lotions, gets, powders, solutions, sprays, inhalants, or patches.
- the active agent is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- cutaneous routes of administration are achieved with aqueous drops, a mist, an emulsion, or a cream.
- Transdermal patches may have the added advantage of providing controlled delivery of the active ingredients to the body.
- dosage forms can be made by dissolving or dispensing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- injectable preparations are also contemplated herein, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- compositions for rectal administration may be suppositories which can be prepared by mixing a MetAP2 inhibitor with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active agent(s).
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active agent(s).
- contemplated formulations can be administered by release from a lumen of an endoscope after the endoscope has been inserted into a rectum of a subject.
- Oral dosage forms such as capsules, tablets, pills, powders, and granules, may be prepared using any suitable process known to the art.
- a MetAP2 inhibitor may be mixed with enteric materials and compressed into tablets.
- formulations of the invention are incorporated into chewable tablets, crushable tablets, tablets that dissolve rapidly within the mouth, or mouth wash.
Abstract
The invention generally relates to methods of treating a male subject with a prostate condition, for example, benign prostate hyperplasia (BPH). In certain embodiments, the invention provides methods of treating a male subject with a prostate condition, which include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.
Description
- This application claims priority to U.S. Ser. No. 61/293,320, tiled Jan. 8, 2010, which is incorporated by reference in its entirety.
- Benign Prostate Hyperplasia (BPH), also called prostate enlargement, occurs in almost all men as they age. About half of men in their 60s have at least some symptoms of BPH. The prostate is the semen-producing gland that surrounds the urethra, the tube that carries urine from the bladder out of the body. Symptoms of BPH result when the prostate gland grows to the extent that it blocks the flow of urine through the urethra. This blockage may cause urinary problems, including an inability to completely empty the bladder, a frequent urge to urinate, a weak urine stream, nocturia, and hematuria. In some cases, these urinary problems lead to more serious complications, including urinary tract infections; bladder damage, stones, or infection; and kidney damage.
- Medications used to control prostate growth include alpha blockers and 5-alpha reductase inhibitors. Alpha blockers may act by relaxing the muscles around the bladder neck, which makes urination easier. Alpha blockers approved by the Food and Drug Administration to treat BPH are terazosin (Hytrin®), doxazosin (Cardura®), tamsulosin (Flomax®) and alfuzosin (Uroxatral®). The long-term effects of alpha-blockers are unknown and side effects include interactions with drugs taken to treat impotence and dizziness and lightheadedness upon standing. 5-alpha reductase inhibitors, such as finasteride (Proscar®) and dutasteride (Avodart®) set by shrinking the prostate. 5-alpha reductase drugs may only be effective in subjects with large prostates and not in subjects with moderately-enlarged or normal-sized prostates. In addition, 5-alpha reductase drugs may take up to a year to produce therapeutic effects, may decrease libido, and may interfere with accurate reading of PSA tests, which are used to diagnose prostate cancer.
- Non-invasive procedures used to treat BPH include transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents. TUMT, TUNA, and ILT involve the use of heat produced by microwaves, radio waves, and lasers, respectively, to destroy prostate tissue blocking the urethra. TUMT, TUNA, and ILT may be less effective for large prostates, and the long-term effectiveness of these procedures is unknown. Prostatic stents are metal coils used to prop open the urethra. Stents are typically used in subjects unwilling or unable to take medications and/or have surgery, and are typically not considered to be a long-term treatment option.
- Surgeries to treat BPH include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, and open prostatectomy. In TURP, a narrow instrument is inserted into the urethra and used to scrape away prostate tissue surrounding the urethra. TUIP is performed similarly to TURP, but only one or two cuts is the prostate are made to relieve the pressure on the urethra. Laser surgery, such as photosensitive vaporization of the prostate (PVP) and holium laser enucleation of the prostate (HoLEP) involve the use of lasers to destroy prostate tissue. In an open prostatectomy, the prostate is accessed through an incision is made in a subject's lower abdomen (rather than through the urethra), and the inner portion of the prostate is removed. A subject who undergoes surgery to treat BPH may require additional surgeries if the prostate grows back. Side effects, such as impotence, incontinence, infection and scarring, may occur.
- Medications, non-invasive procedures and surgeries known in the art for treating BPH may not be as effective as desired and often produce side effects. Methods of treating subjects with BPH that are more effective than current therapies, e.g., surgery, are clearly needed.
- At least in part, this disclosure provides for a method for treating benign prostatic hypertrophy (BPH) and related disorders, in a male subject in need thereof, comprising administering (e.g. parenterally, intravenously, subcutaneously, orally), a therapeutically effective amount of a MetAP-2. Such methods may result in reduction in the rate of growth of the subject's prostate, for example, such methods may provide for a decrease in the prostate of said male subject by at least 25% within 30 days.
- Provided methods may provide that at least one of sperm viability, motility, quantity, and rate of production are not substantially. Contemplated MetAP-2 inhibitors include fumagillin-based compounds.
- Provided methods, may, in some embodiments, further comprise administering an additional therapeutic agent, for example, an alpha blocker (e.g. terazosin, doxazosin, tamsulosin and alfuxosin), a 5 alpha reductase inhibitor (e.g. finasteride and dutasteride), saw palmetto, beta-sitosterol, and pygeum. In another embodiment, contemplated methods may further comprise administering a non-invasive procedure, such as transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), or prostatic stents, and/or may further comprise administering a surgical treatment, such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, or open prostatectomy.
- Exemplary MetAP-2 inhibitors may be, for example, represented by Compound 1:
- or a pharmaceutically acceptable salt thereof.
- MetAP-2 inhibitors may be administered as a dose of about 0.01 mg/kg to about 10 mg/kg, or about 0.04 mg/kg to about 1.0 mg/kg.
- Also provided herein is a method for reducing the prostate gland in a male subject in need thereof, comprising administering a therapeutically effective amount of a MetAP-2 inhibitor to the male subject.
- The disclosure relays at least in part to methods for treating a prostate condition, such as BPH, which include administering a MetAP2 inhibitor. MetAP2 encodes a protein that functions at least in part by enzymatically removing the amino terminal methionine residue from certain newly translated proteins. Increased expression of the MetAP2 gene has been historically associated with various forms of cancer. Molecules inhibiting the enzymatic activity of MetAP2 have been identified and have been explored for their utility in the treatment of various tumor types (Wang et al. (2003) Cancer Res. 63:7861) and infectious diseases such as microsporidiosis, leishmaniasis, and malaria (Zhang et a). (2002) J. Biomed. Sci. 9:34). While BPH is not a form of cancer, it has been found that MetAP2 inhibitors can effectively treat subjects with BPH. Disclosed herein are methods relating to administering a MetAP-2 inhibitor to treat a prostate condition, e.g., BPH.
- BPH may be diagnosed based on an evaluation of a subject's reported symptoms and family history, as well as by the results of one or more tests including a digital rectal exam, urine test, blood test, transrectal ultrasound (TRUS), urodynamic pressure-flow studies, cystoscopy, intravenous pyelogram or CT urogram, prostate-specific antigen (PSA) blood test, urinary flow test and postvoid residual volume test.
- MetAP2 inhibitors refer to a class of molecules that inhibit the activity of MetAP2, e.g., the ability of MetAP2 to cleave the N-terminal methionine residue of newly synthesized proteins to produce the active form of the protein, or the ability of MetAP2 to regulate protein synthesis by protecting the sub-unit of eukaryotic initiation factor-2 (eIf2) from phosphorylation.
- Exemplary MetAP2 inhibitors may include irreversible inhibitors that covalently bind to MetAP2. For example, such irreversible inhibitors include fumagillin, fumagillol, and fumagillin ketone.
- Derivatives and analogs of fumagillin, and pharmaceutically acceptable salts thereof are contemplated herein as irreversible MetAP2 inhibitors, such as O-(4-dimethylaminoethoxycinnamoyl)fumagillol (CKD-732, also referred to herein as Compound A), O-(3,4,5-trimethoxycinnamoyl)fumagillol, O-(4-chlorocinnamoyl)fumagillol; O-(4-aminocinnamoyl)fumagillol; O-(4-dimethylaminoethoxycinnamoyl)fumagillol; O-(4-methoxycinnamoyl)fumagillol O-(4-dimethylaminocinnamoyl)fumagillol; O-(4-hydroxycinnamoyl)fumagillol; O-(3,4-dimethoxycinnamoyl)fumagillol; O-(3,4-methylenedioxycinnamoyl)fumagillol; O-(3,4,5-trimethoxycinnamoyol)fumagillol; O-(4-nitrocinnamoyl)fumagillol; O-(3,4-dimethoxy-6-aminocinnamoyl)fumagillol; O-(4-acetoxy-3,5-dimethoxycinnamoyl)fumagillol; O-(4-ethylaminocinnamoyl)fumagillol; O-(4-ethylaminoethoxycinnamoyl)fumagillol; O-(3-dimethylaminomethyl-4-methoxycinnamoyl)fumagillol; O-(4-trifluoromethylcinnamoyl)fumagillol; O-(3,4-dimethoxy-6-nitrocinnamoyl)fumagillol; O-(4-acetoxycinnamoyl)fumagillol; O-(4-cyanocinnamoyl)fumagillol; 4-(4-methoxycinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol; O-(3,4,5-trimethoxycinnamoyl)fumagillol; O-(4-dimethylaminocinnamoyl)fumagillol; O-(-3,4,5-trimethoxycinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol; O-(4-dimethylaminocinnamoyl)oxy-2-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-3-methoxy-1-chloromethyl-1-cyclohexanol; O-(3,5-dimethoxy-4-hydroxycinnamoyl)fumagillol or O-(chloracetyl-carbamoyl)fumagillol (TNP-470).
- Fumagillin, and some derivatives thereof, have a carboxylic acid moiety and can be administered in the form of the free acid. Alternatively, contemplated herein are pharmaceutically acceptable salts of fumagillin, fumagillol, and derivatives thereof. Pharmaceutically acceptable salts illustratively include those that can be made using the following bases: ammonia, L-arginine, benethamine, benzathene, betaine, bismuth, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)morpholine, piperazine, potassium hydroxide, 1-(2-hydroxyethyl)pyrrolidine, sodium hydroxide, triethanolamine, zinc hydroxide, dicyclohexlamine, or any other electron pair donor (as described in Handbook of Pharmaceutical Salts, Stan & Wermuth, VHCA and Wiley, Uchsenfurt-Hohestadt Germany, 2002), Contemplated pharmaceutically acceptable salts may include hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, trifluoroacetic acid, oxalic acid, fumaric acid, tartaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid or para-toluenesulfonic acid.
- Esters of the present invention may be prepared by reacting fumagillin or fumagillol with the appropriate acid under standard esterification conditions described in the literature (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis). Suitable fumagillin esters include ethyl methanoate, ethyl ethanoate, ethyl propanoate, propyl methanoate, propyl ethanoate, and methyl butanoate.
- In another embodiment, contemplated, irreversible inhibitors of MetAP2 may include a siRNA, shRNA, an antibody or an antisense compound of MetAP2.
- Further examples of MetAP2 inhibitors, are provided in the following references, each of which is hereby incorporated by reference; Olson et al. (U.S. Pat. No. 7,084,108 and WO 2002/042295), Olson et al. (U.S. Pat. No. 6,548,477; U.S. Pat. No. 7,037,890; U.S. Pat. No. 7,084,108; U.S. Pat. No. 7,268,111; and WO 2002/042295), Olson et al. (WO 2005/066197), Hong et al. (U.S. Pat. No. 6,040,337), Hong et al. (U.S. Pat. No. 6,063,812 and WO 1999/059986), Lee et al. (WO 2006/080591), Kishimoto et al. (U.S. Pat. No. 5,166,172; U.S. Pat. No. 5,698,586; U.S. Pat. Nos. 5,164,410; and 5,180,738), Kishimoto et al. (U.S. Pat. No. 3,180,735), Kishimoto et al. (U.S. Pat. No. 5,288,722), Kishimoto et al. (U.S. Pat. No. 5,204,345), Kishimoto et al. (U.S. Pat. No. 5,422,363), Liu et al. (U.S. Pat. No. 6,207,704; U.S. Pat. No. 6,566,541; and WO 1998/056372), Craig et al. (WO 1999/057097), Craig et al. (U.S. Pat. No. 6,242,494), BaMaung et al. (U.S. Pat. No. 7,030,2S2), Comess et al. (WO 2004/033419), Comess et al. (US 2004/0157836), Comess et al. (US 2004/0167128), Henkin et al. (WO 2002/083065), Craig et al. (U.S. Pat. No. 6,887,863), Craig et al. (US 2002/0002152), Sheppard et al. (2004, Bioorganic & Medicinal Chemistry Letters 14:865-868), Wang et al. (2003, Cancer Research 63:7861-7869), Wang et al. (2007, Bioorganic & Medicinal Chemistry Letters 17:2817-2822), Kawai et al. (2006, Bioorganic & Medicinal Chemistry Letters 16:3574-3577), Henkin et al. (WO 2002/026782), Nan et al. (US 2005/0113420), Luo et al. (2003, J. Med. Chem., 46:2632-2640), Vedantham et al. (2008, J. Comb. Chem., 10:195-205), Wang et al. (2008, J. Med. Chem 51:6110-20), Ma et al. (2007, BMC Structural Biology, 7:84) and Huang et al. (2007, J. Med. Chem., 50:5735-5742), Evdokimov et al. (2007, PROTEINS: Structure, Function, and Bioinformatics, 66:538-546), Garrabrant et al. (2004, Angiogenesis 7:91-96), Kim et al. (2004, Cancer Research, 64:2984-2987), Towbin et al (2003, The Journal of Biological Chemistry, 278(52):52964-52971), Marino Jr. (U.S. Pat. No. 7,304,082), Kallender et al. (U.S. patent application number 2004/0192914), and Kallender at (U.S. patent application numbers 2003/0220371 and 2005/0004116). In some embodiments, contemplated MetAP2 inhibitors do not include fumagillin, fumagillol, fumagillin ketone, CKD-732/compound A, and/or TNP-470.
- For example, contemplated MetAP2 inhibitors may include:
- A method of treating a condition affecting the prostate, e.g., benign prostate hyperplasia (BPH), in a subject in need thereof is provided herein, comprising parenterally or non-parenterally administering a therapeutically effective amount of a MetAP2 inhibitor to said subject. In some embodiments, a contemplated therapeutically effective amount of a MetAP2 as described below, does not substantially modulate or suppress angiogenesis, but is still effective as MetAP2 inhibitor. The term “angiogenesis” is known to persons skilled in the art, and refers to the process of new blood vessel formation, and is essential for the exponential growth of solid tumors and tumor metastasis. For example, provided herein is a method of treating a condition affecting the prostate in a subject in need thereof, comprising administering a therapeutically effective amount of a MetAP2 inhibitor to said subject, wherein substantially no loss of new blood vessels in the prostate or other tissue compartments occur as compared to a subject being treated for a prostate condition with, e.g., surgery.
- In some embodiments, disclosed methods, upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in a reduction in the rate of prostate growth in a male-subject of at least a 5%, 10%, 20%, or 30%, or more based on the prostate's original rate of growth. In some embodiments, disclosed methods, upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in a reduction in the size of a prostate of at least a 5%, 10%, 20%, or 30%, or more based on the original size of the prostate. In an embodiment, reduction in size of the prostate following treatment with therapeutically effective doses of MetAP2 inhibitors may substantially cease once a subject attains a desired prostate size, i.e., a size that reduces and/or eliminates symptoms, e.g. urinary symptoms, of a prostate condition, e.g. BPH.
- Some methods disclosed herein may involve co-administration of another BPH treatment, such as a therapeutic agent. Therapeutic agents include but are not limited to alpha blockers, e.g., terazosin (Hytrin®), doxazosin (Cardura®), tamsulosin (Flomax®) and alfuzosin (Uroxatral®), 5-alpha reductase inhibitors, e.g., finasteride (Proscar®) and dutasteride (Avodart®), saw palmetto, beta-sitosterol, and pygeum. In some embodiments, contemplated methods include co-administration of a non-invasive procedure, e.g., transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents. Further embodiments include coadministering a surgical treatment, e.g. transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, and open prostatectomy.
- In some embodiments, co-administration of a MetAP-2 inhibitor and another BPH treatment occur at the same time. In other embodiments, administration of a MetAP-2 inhibitor occurs immediately prior to or immediately after another BPH treatment. In yet another embodiment, a period of time may elapse between administration of a MetAP-2 inhibitor and another BPH treatment. For example, a male subject may be administered prostate surgery to reduce the size of the prostate, followed by a recovery period of, e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, or 6 months or longer, after which time the male subject is administered a MetAP-2 inhibitor to reduce the rate of re-growth of the prostate.
- Contemplated herein are formulations suitable for parenteral or non-parenteral administration of MetAP2 inhibitors. In certain embodiments, a subject may have a lower systemic exposure (e.g. at least about 2, 3, 5, 10, 20, or at least about 30% less systemic exposure) to the non-parenterally (e.g. orally) administered of a MetAP2 inhibitor as compared to a subject parenterally (e.g. subcutaneously) administered the same dose of the MetAP2 inhibitor. For example, non-parenterally (e.g. orally) administered MetAP2 inhibitors may bind less to MetAP2 as compared to parenterally (e.g. subcutaneously) administered MetAP2 inhibitors.
- Contemplated non-parenteral administration includes oral, buccal, transdermal (e.g. by a dermal patch), topical, inhalation, sublingual, ocular, pulmonary, nasal, or rectal administration.
- Contemplated parenteral administration includes intravenous and subcutaneous administration, as well as administration at a site of a minimally-invasive procedure or a surgery.
- In another embodiment, provided herein are effective dosages, e.g. a daily dosage of a MetAP2 inhibitor, that may not substantially modulate or suppress angiogenesis. For example, provided here are methods that include administering doses of MetAP2 inhibitors that are effective for reducing the rate of growth of the prostate, but are significantly smaller doses than that necessary to modulate and/or suppress angiogenesis (which may typically require about 12.5 mg/kg to about 50 mg/kg or more). For example, contemplated dosage of a MetAP2 inhibitor in the methods described herein may include administering about 25 mg/day, about 10 mg/day, about 5 mg/day, about 3 mg/day, about 2 mg/day, about 1 mg/day, about 0.75 mg/day, about 0.5 mg/day, about 0.1 mg/day, about 0.05 mg/day, or about 0.01 mg/day.
- For example, an effective amount of the drug for reducing the rate of prostate growth in a male subject may be about 0.0001 mg/kg to about 25 mg/kg of body weight per day. For example, a contemplated dosage may from about 0.001 to 10 mg/kg of body weight per day, about 0.001 mg/kg to 1 mg/kg of body weight per day, about 0.001 mg/kg to 0.1 mg/kg of body weight per day or about 0.005 to about 0.04 mg/kg or about 0.005 to about 0.049 mg/kg of body weight a day. In an embodiment a MetAP2 inhibitor such as disclosed herein (e.g. O-(4-dimethylaminoethyoxycinnamoyl)fumagillol); may be administered about 0.005 to about 5 mg/kg, or so about 5 mg/kg, or about 0.005 to about 0.1 mg/kg of a subject.
- For example, provided herein is a method for treating a prostate condition in a male subject in need thereof, comprising administering, parenterally (e.g. intravenously) or non-parenterally, about 0.005 to about 0.04 mg/kg of a MetAP2 inhibitor selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable-salts thereof (for example, an oxalate salt), to said subject. Such a method, upon administration of said MetAP2 inhibitor e.g. daily or weekly, for about 3, 4, 5 or 6 months or more may result in at least a 10%, 20%, 30%, or 40% or more reduction in the rate of growth of the prostate.
- Contemplated methods may include administration of a composition comprising a MetAP2 inhibitor, for example, hourly, twice hourly, every three to four hours, daily, twice daily, 1, 2, 3 or 4 times a week, every three to four days, every week, or once every two weeks depending on half-life and clearance rate of the particular composition or inhibitor.
- Treatment can be continued for as long or as short a period as desired. The compositions may be administered on a regimen of, for example, one to four or more times per day. A suitable treatment period may be, for example, at least about one week, at least about two weeks, at least about one month, at least about six months, at least about 1 year, or indefinitely. A treatment period may terminate when a desired result, for example desired prostate size, is achieved. For example, treatment may terminate when reduction of about 20% of the prostate, about 30% of the prostate or more has been achieved. A treatment regimen may include a corrective phase, during which a MetAP2 inhibitor dose sufficient to provide reduction of prostate size is administered, followed by a maintenance phase, during which a lower MetAP2 inhibitor dose sufficient to reduce or prevent growth is administered.
- For pulmonary (e.g., intrabronchial) administration, MetAP2 inhibitors may be formulated with conventional excipients to prepare an inhalable composition in the form of a fine powder or atomizable liquid. For ocular administration, MetAP2 inhibitors may be formulated with conventional excipients, for example, in the form of eye drops or an ocular implant. Among excipients useful in eye drops are viscosifying or gelling agents, to minimize loss by lacrimation through improved retention in the eye.
- Liquid dosage forms for oral, or other administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active agent(s), the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl-alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the ocular, oral, or other systemically-delivered compositions can also include adjuvants such as wetting agents, and emulsifying and suspending agents.
- Dosage forms for topical or transdermal administration of an inventive pharmaceutical composition may include ointments, pastes, creams, lotions, gets, powders, solutions, sprays, inhalants, or patches. The active agent is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. For example, cutaneous routes of administration are achieved with aqueous drops, a mist, an emulsion, or a cream.
- Transdermal patches may have the added advantage of providing controlled delivery of the active ingredients to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
- When administered in lower doses, injectable preparations are also contemplated herein, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- Compositions for rectal administration may be suppositories which can be prepared by mixing a MetAP2 inhibitor with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active agent(s). Alternatively, contemplated formulations can be administered by release from a lumen of an endoscope after the endoscope has been inserted into a rectum of a subject.
- Oral dosage forms, such as capsules, tablets, pills, powders, and granules, may be prepared using any suitable process known to the art. For example, a MetAP2 inhibitor may be mixed with enteric materials and compressed into tablets.
- Alternatively, formulations of the invention are incorporated into chewable tablets, crushable tablets, tablets that dissolve rapidly within the mouth, or mouth wash.
- This example is not intended in any way to limit the scope of this invention but is provided to illustrate aspects of the disclosed methods. Many other embodiments of this invention will be apparent to one skilled in the art.
- Male rats were divided into a control group and three test groups with 20 animals per group. Animals were administered the MetAP-2 inhibitor Compound I, represented by the formula:
- Compound I was prepared in a 5% mannitol solution was administered once daily for four weeks by a fifteen-minute intravenous infusion according to Table I.
-
TABLE 1 Dosage Dose Dose Group Test Level Concentration Volume Infusion Rate Number of Number Article (mg/kg/day) (mg/mL) (mL/kg) (mL/kg/min) Males 1 Vehicle 0 0 3.75 0.25 20 Control 2 Compound 1 0.04 0.01 3.75 0.25 20 3 Compound 1 0.2 0.053 3.75 0.25 20 4 Compound 1 1.0 0.266 3.75 0.25 20 - Ten animals from each group were euthanized the end of the four weeks.
- The remaining ten animals were allowed to recover for 10 additional weeks and were then euthanized. Body weights and organ weights (absolute and relative to body weights) were determined and are shown in Table II.
-
TABLE II Group 0 mg/kg/day (Vehicle 0.04 mg/ 0.2 mg/ 1.0 mg/ Control) kg/day kg/day kg/day Final Body Weight (g) Mean 477 437** 411** 393** Standard Deviation 37.8 28.9 19.4 17.9 N 10 10 10 10 Protate Weight (g) Mean 1.23 0.90** 0.89** 0.76** Standard Deviation 0.255 0.188 0.166 0.190 N 10 10 10 10 **Significantly different from the control group at 0.01 using Dunnett's test - Administration of a MetAP-2 inhibitor at all doses causes a reduction in the weight of the prostate gland in male animals.
- References and citations to other documents, such as patents, patent applications, patent publications, journals, boobs, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
- Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims (19)
1. A method for treating benign prostatic hypertrophy (BPH) in a male subject in need thereof, comprising administering a therapeutically effective amount of a MetAP-2 inhibitor to said male subject.
2. The method of claim 1 , wherein the MetAP-2 inhibitor is a fumagillin-based compound.
3. The method of claim 1 , wherein the method results in a reduction in the rate of growth of the subject's prostate.
4. The method of claim 1 , wherein upon administration, the prostate of said male subject decreases by at least 25% within 30 days.
5. The method of claim 1 , wherein administration occurs parenterally.
6. The method of claim 1 , wherein administration is intravenous or subcutaneous.
7. The method of claim 1 , wherein at least one of sperm viability, motility, quantity, and rate of production are not substantially decreased after administration of said MetAP-2 inhibitor.
8. The method of claim 1 , further comprising administering an additional therapeutic agent.
9. The method of claim 8 , wherein the additional therapeutic agent is selected from the group consisting of an alpha blocker, a 5 alpha reductase inhibitor, saw palmetto, beta-sitosterol, and pygeum.
10. The method of claim 9 , wherein the alpha blocker is selected from the group consisting of terazosin, doxazosin, tamsulosin and alfuzosin.
11. The method of claim 9 , wherein the 5 alpha reductase inhibitor is selected from the group consisting of finasteride and dutasteride.
12. The method of claim 1 , further comprising administering a non-invasive procedure.
13. The method of claim 12 , wherein the non-invasive procedure is selected from the group consisting of transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), interstitial laser therapy (ILT), and prostatic stents.
14. The method of claim 1 , further comprising administering a surgical treatment.
15. The method of claim 14 , wherein the surgical treatment is selected from the group consisting of transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), laser surgery, and open prostatectomy.
17. The method of claim 1 , wherein the MetAP-2 inhibitor is administered at a dose of about 0.01 mg/kg to about 10 mg/kg.
18. The method of claim 1 , wherein the MetAP-2 inhibitor is administered at a dose of about 0.04 mg/kg to about 1.0 mg/kg.
19. A method for reducing the prostate gland in a male subject in need thereof, comprising administering a therapeutically effective amount of a MetAP-2 inhibitor to a male subject in need thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/327,097 US20150157595A1 (en) | 2010-01-08 | 2014-07-09 | Methods of treating a subject with benign prostate hyperplasia |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29332010P | 2010-01-08 | 2010-01-08 | |
PCT/US2011/020515 WO2011085198A1 (en) | 2010-01-08 | 2011-01-07 | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
US201213520744A | 2012-11-13 | 2012-11-13 | |
US14/327,097 US20150157595A1 (en) | 2010-01-08 | 2014-07-09 | Methods of treating a subject with benign prostate hyperplasia |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/520,744 Continuation US8815309B2 (en) | 2010-01-08 | 2011-01-07 | Methods of treating a subject with benign prostate hyperplasia |
PCT/US2011/020515 Continuation WO2011085198A1 (en) | 2010-01-08 | 2011-01-07 | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150157595A1 true US20150157595A1 (en) | 2015-06-11 |
Family
ID=43858365
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/520,744 Expired - Fee Related US8815309B2 (en) | 2010-01-08 | 2011-01-07 | Methods of treating a subject with benign prostate hyperplasia |
US14/327,097 Abandoned US20150157595A1 (en) | 2010-01-08 | 2014-07-09 | Methods of treating a subject with benign prostate hyperplasia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/520,744 Expired - Fee Related US8815309B2 (en) | 2010-01-08 | 2011-01-07 | Methods of treating a subject with benign prostate hyperplasia |
Country Status (2)
Country | Link |
---|---|
US (2) | US8815309B2 (en) |
WO (1) | WO2011085198A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
JP5890312B2 (en) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | Sulfone compounds used in the treatment of obesity |
KR101696960B1 (en) | 2010-01-08 | 2017-01-16 | 자프겐 인크. | Fumagillol type compounds and methods of making and using same |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
KR20130043207A (en) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | Tricyclic compounds and methods of making and using same |
DE102010048374A1 (en) | 2010-10-13 | 2012-04-19 | Merck Patent Gmbh | Pyrrolidinones as MetAP-2 inhibitors |
JP2013543899A (en) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | Treatment of obesity with non-daily administration of 6-O- (4-dimethylaminoethoxy) cinnamoyl fumagillol |
WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
CA2835209A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
CN103764641B (en) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | The tricyclic compound of fractional saturation and preparation and application thereof |
AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
CA2861390A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CN104169268A (en) | 2012-01-18 | 2014-11-26 | 扎夫根股份有限公司 | Tricyclic sulfone compounds and methods of making and using same |
DE102012006884A1 (en) | 2012-04-04 | 2013-10-10 | Merck Patent Gmbh | Cyclic amides as MetAP-2 inhibitors |
JP2015516426A (en) | 2012-05-08 | 2015-06-11 | ザフゲン,インコーポレイテッド | Treatment of hypothalamic obesity with MetAP2 inhibitors |
JP6177888B2 (en) | 2012-05-09 | 2017-08-09 | ザフゲン,インコーポレイテッド | Fumagillol type compound and method for producing and using the same |
JP6169716B2 (en) | 2012-11-05 | 2017-07-26 | ザフゲン,インコーポレイテッド | How to treat liver disease |
MX2015005732A (en) | 2012-11-05 | 2015-12-16 | Zafgen Inc | Tricyclic compounds and methods of making and using same. |
CN104918928A (en) | 2012-11-05 | 2015-09-16 | 扎夫根股份有限公司 | Tricyclic compounds for use in the treatment and/or control of obesity |
EP2968250B1 (en) * | 2013-03-14 | 2019-06-19 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
TW201613572A (en) * | 2014-08-22 | 2016-04-16 | Zafgen Inc | Formulations having a METAP-2 inhibitor |
CN106432255A (en) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | Fumigillol spiro-compound, preparation and use method thereof |
AR105671A1 (en) | 2015-08-11 | 2017-10-25 | Zafgen Inc | HUMEROCYCLIC COMPOUNDS OF FUMAGILLOL AND ITS METHODS OF ELABORATION AND USE |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
DE68927904T2 (en) | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol derivatives |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
EP0387650B1 (en) | 1989-03-06 | 1993-03-31 | Takeda Chemical Industries, Ltd. | 6-epifumagillols, production and use thereof |
US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
TW282399B (en) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
EP0602586B1 (en) | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
JP3260378B2 (en) | 1995-03-27 | 2002-02-25 | サノフィーサンテラボ | Use of fumagillol and its derivatives for the preparation of a drug against intestinal infection |
CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
US6306819B1 (en) | 1997-10-31 | 2001-10-23 | Massachusetts Institute Of Technology | Method for regulating size of vascularized normal tissue |
US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
KR100357541B1 (en) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-Demthoxyfumagillol derivatives and processes for preparing the same |
KR100357542B1 (en) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | Fumagillol derivatives and preparation method thereof |
KR100293504B1 (en) * | 1998-06-05 | 2001-07-12 | 김윤 | Sustanined-releasing anti-prostatitic composition and preparing method thereof |
JP2000116337A (en) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | Pet food |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
AU782404B2 (en) | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
WO2001024796A1 (en) | 1999-10-01 | 2001-04-12 | Smithkline Beecham Corporation | 1,2,4-triazole derivatives, composition, process of making and methods of use |
JP2003530438A (en) | 2000-04-12 | 2003-10-14 | スミスクライン・ビーチャム・コーポレイション | Compounds and methods |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
PE20020376A1 (en) | 2000-09-29 | 2002-05-13 | Abbott Lab | ANTIANGIOGENIC POLYPEPTIDES AND METHODS TO INHIBIT ANGIOGENESIS |
AU3947902A (en) | 2000-11-01 | 2002-06-03 | Praecis Pharm Inc | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
JP2004525942A (en) | 2001-03-29 | 2004-08-26 | スミスクライン・ビーチャム・コーポレイション | Compounds and methods |
US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
DE60233420D1 (en) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillol derivatives and process for their preparation |
WO2003031434A1 (en) | 2001-10-12 | 2003-04-17 | Smith Kline Beecham Corporation | Compounds and methods |
US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
KR100451485B1 (en) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
CN100357283C (en) | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | Methionyl aminopeptidase inhibitor |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
US20050239878A1 (en) | 2003-12-29 | 2005-10-27 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
KR100552043B1 (en) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | Composition for obesity treatment comprising fumagillol derivatives |
EP1781303A4 (en) | 2004-06-30 | 2008-07-02 | Combinatorx Inc | Methods and reagents for the treatment of metabolic disorders |
WO2006010498A2 (en) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
WO2006080591A1 (en) | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
FR2886855B1 (en) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | USE OF FUMAGILLIN AND ITS DERIVATIVES TO INCREASE BIODAVAILABILITY OF MACROCYLIC LACTONES |
WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
NZ585547A (en) | 2007-11-28 | 2012-12-21 | Mersana Therapeutics Inc | Biocompatible biodegradable fumagillin analog conjugates |
EP2317845A4 (en) | 2008-07-18 | 2011-11-09 | Zafgen Inc | Methods of treating an overweight or obese subject |
US8729097B2 (en) | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
WO2010048499A1 (en) | 2008-10-24 | 2010-04-29 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
WO2010065879A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
JP5890312B2 (en) | 2009-10-09 | 2016-03-22 | ザフゲン,インコーポレイテッド | Sulfone compounds used in the treatment of obesity |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
KR101696960B1 (en) | 2010-01-08 | 2017-01-16 | 자프겐 인크. | Fumagillol type compounds and methods of making and using same |
WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
KR20130043207A (en) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | Tricyclic compounds and methods of making and using same |
AU2011316550A1 (en) | 2010-10-12 | 2013-05-02 | Zafgen, Inc | Sulphonamide compounds and methods of making and using same |
MY177039A (en) | 2010-11-09 | 2020-09-03 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
US20130316994A1 (en) | 2010-11-29 | 2013-11-28 | Zafgen, Inc. | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors |
JP2013543899A (en) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | Treatment of obesity with non-daily administration of 6-O- (4-dimethylaminoethoxy) cinnamoyl fumagillol |
WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
JP5876513B2 (en) | 2011-03-08 | 2016-03-02 | ザフゲン,インコーポレイテッド | Oxaspiro [2.5] octane derivatives and analogs |
AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CN103764641B (en) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | The tricyclic compound of fractional saturation and preparation and application thereof |
CA2835209A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
CA2861390A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
CN104169268A (en) | 2012-01-18 | 2014-11-26 | 扎夫根股份有限公司 | Tricyclic sulfone compounds and methods of making and using same |
MX2014013525A (en) | 2012-05-07 | 2015-10-22 | Zafgen Inc | Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same. |
JP2015516426A (en) | 2012-05-08 | 2015-06-11 | ザフゲン,インコーポレイテッド | Treatment of hypothalamic obesity with MetAP2 inhibitors |
JP6177888B2 (en) | 2012-05-09 | 2017-08-09 | ザフゲン,インコーポレイテッド | Fumagillol type compound and method for producing and using the same |
-
2011
- 2011-01-07 US US13/520,744 patent/US8815309B2/en not_active Expired - Fee Related
- 2011-01-07 WO PCT/US2011/020515 patent/WO2011085198A1/en active Application Filing
-
2014
- 2014-07-09 US US14/327,097 patent/US20150157595A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130052283A1 (en) | 2013-02-28 |
WO2011085198A1 (en) | 2011-07-14 |
US8815309B2 (en) | 2014-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8815309B2 (en) | Methods of treating a subject with benign prostate hyperplasia | |
US7015253B2 (en) | Regimen for treating prostate tissue and surgical kit for use in the regimen | |
US20140073691A1 (en) | Methods and composition for Treating Thyroid Hormone Related Disorders | |
US20140248263A1 (en) | Bisphenol compounds and methods for their use | |
US20130316994A1 (en) | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors | |
AU738306B2 (en) | Means for treating prostate hypertrophy and prostate cancer | |
US20160166531A1 (en) | Methods and compositions for treating cardiovascular disorders | |
SK14762003A3 (en) | Skin-permeable composition comprising a selective cyclooxygenase- 2 inhibitor a monohydric alcohol | |
US20090105282A1 (en) | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using pde 5 inhibitors | |
CN111265503B (en) | Composition for inhibiting activity of 5 alpha-reductase and application thereof | |
Zvara et al. | Ablation of canine prostate using transurethral intraprostatic absolute ethanol injection | |
KR20050096135A (en) | Method of treatment of prostate cancer and composition for treatment thereof | |
Bearelly et al. | The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction | |
Lusuardi et al. | New emerging technologies in benign prostatic hyperplasia | |
EP2363397A1 (en) | Novel useful therapeutic agent for lower urinary tract symptom | |
WO2022262854A1 (en) | Cly series compound, preparation method therefor and use thereof in preparation of drugs | |
AU2017445169B2 (en) | Multikinase inhibitors and uses in prostatic hyperplasia and urinary tract diseases | |
ES2365387T3 (en) | ANALGESIC AND ANTIFLAMATORY COMPOSITIONS CONTAINING CELECOXIB AND IBUPROFEN. | |
KR20130115650A (en) | The liquified composition comprising of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide compound | |
Leonardi et al. | Endoscopic laser en bloc removal of bladder tumor. Surgical radicality and improvement of the pathological diagnostic accuracy | |
EP2172201A1 (en) | Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly | |
US20100305144A1 (en) | Prevention of recurrence of urethral stricture after a conventional treatment | |
EP1990048A2 (en) | Therapy of benign prostatic hyperplasia (bph) | |
EP2223690A1 (en) | Pharmaceutical composition for ameliorating lower urinary tract symptom | |
Buchholz et al. | Transurethral ethanol ablation of prostate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |